Complex ABO Glycan Phenotypes Predicted by Lectin Microarrays
|
By LabMedica International staff writers Posted on 16 Sep 2020 |

Image: The LecChip and GlycoStation were used to identify subtle surface ABO blood group glycoprotein density variations (Photo courtesy of Glycotechnica).
Serological classification of individuals as A, B, O, or AB is a mainstay of blood banking. ABO blood groups or ABH antigens, in addition to other surface glycans, act as unique red blood cell (RBC) signatures and direct immune responses. ABO subgroups present as weakened, mixed field, or unexpected reactivity with serological reagents, but specific designations remain complex.
Lectins detect glycan motifs with some recognizing ABH antigens. Adaption of high-throughput microarrays spotted with a multitude of lectins, including lectins that recognize blood groups, may complement current methods for a more thorough interpretation of RBC ABH expression. Although many lectins have the ability to bind unique blood group antigens, few are tested for ABO-specific agglutination and, thus, limit their use in transfusion medicine.
Medical scientists at the Medical College of Wisconsin (Milwaukee, WI, USA) evaluated a 45-probe lectin microarray to rapidly analyze ABO blood groups and associated unique glycan signatures within complex biological samples on RBC surface glycoproteins. RBC membrane glycoproteins were prepared from donor RBCs, using 20 samples for each blood group. ABO blood group was distinguishable by lectin array, including variations in ABH antigen expression not observed with serology.
The total protein content from each extracted cell fraction was determined using the Micro BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). The LecChip (Glycotechnica, Yokohama, Japan) was chosen as a testing platform because it provided a wide selection of lectins compared with other commercially available microarrays. Fluorescent microarray images were acquired using the Glycotechnica evanescent-field fluorescence scanner, GlycoStation Reader 2200. Samples were applied in a grid format to the membrane PVDF membranes for immunoblotting.
The team used principal component analysis and highlighted broad ABO blood group clusters with unexpected high and low antigen expression and variations were confirmed with ABH antibody immunoblotting. Using a subset of lectins provided an accurate method to predict an ABO serological phenotype. Lectin microarray highlighted the importance of ABO localization on glycoproteins and glycolipids and pointed to increased glycocalyx complexity associated with the expression of A and B antigens including high mannose and branched polylactosamine. Thus, lectins identified subtle surface ABO blood group glycoprotein density variations not detected by routine serological methods.
The authors concluded that their study showed that ABH antigens on RBC glycoproteins were distinguishable by lectin array. Their analysis was limited to interrogating glycoproteins, but highlighted the importance of ABH localization on glycoproteins even within the same blood group. They identified changes associated with the expression of A and B antigens with increased levels of terminal and high mannose and branching polylactosamine. The study was published on August 21, 2020 in the journal Blood Advances.
Related Links:
Medical College of Wisconsin
Thermo Fisher Scientific
Glycotechnica
Lectins detect glycan motifs with some recognizing ABH antigens. Adaption of high-throughput microarrays spotted with a multitude of lectins, including lectins that recognize blood groups, may complement current methods for a more thorough interpretation of RBC ABH expression. Although many lectins have the ability to bind unique blood group antigens, few are tested for ABO-specific agglutination and, thus, limit their use in transfusion medicine.
Medical scientists at the Medical College of Wisconsin (Milwaukee, WI, USA) evaluated a 45-probe lectin microarray to rapidly analyze ABO blood groups and associated unique glycan signatures within complex biological samples on RBC surface glycoproteins. RBC membrane glycoproteins were prepared from donor RBCs, using 20 samples for each blood group. ABO blood group was distinguishable by lectin array, including variations in ABH antigen expression not observed with serology.
The total protein content from each extracted cell fraction was determined using the Micro BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). The LecChip (Glycotechnica, Yokohama, Japan) was chosen as a testing platform because it provided a wide selection of lectins compared with other commercially available microarrays. Fluorescent microarray images were acquired using the Glycotechnica evanescent-field fluorescence scanner, GlycoStation Reader 2200. Samples were applied in a grid format to the membrane PVDF membranes for immunoblotting.
The team used principal component analysis and highlighted broad ABO blood group clusters with unexpected high and low antigen expression and variations were confirmed with ABH antibody immunoblotting. Using a subset of lectins provided an accurate method to predict an ABO serological phenotype. Lectin microarray highlighted the importance of ABO localization on glycoproteins and glycolipids and pointed to increased glycocalyx complexity associated with the expression of A and B antigens including high mannose and branched polylactosamine. Thus, lectins identified subtle surface ABO blood group glycoprotein density variations not detected by routine serological methods.
The authors concluded that their study showed that ABH antigens on RBC glycoproteins were distinguishable by lectin array. Their analysis was limited to interrogating glycoproteins, but highlighted the importance of ABH localization on glycoproteins even within the same blood group. They identified changes associated with the expression of A and B antigens with increased levels of terminal and high mannose and branching polylactosamine. The study was published on August 21, 2020 in the journal Blood Advances.
Related Links:
Medical College of Wisconsin
Thermo Fisher Scientific
Glycotechnica
Latest Clinical Chem. News
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
- Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection
- Breath Test Could Help Detect Blood Cancers
- ML-Powered Gas Sensors to Detect Pathogens and AMR at POC
- Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation
- Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
- New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs

- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








